Ignite Creation Date:
2024-06-16 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06455267
Status:
RECRUITING
Last Update Posted:
2024-06-12
First Post:
2024-05-23
Brief Title:
Preliminary Clinical Study on the Effect of L-ornithine on the Efficacy of Ustekinumab in Patients With Crohns Disease
Sponsor:
The Third Xiangya Hospital of Central South University
Organization:
The Third Xiangya Hospital of Central South University
Study Overview
Official Title:
A Single Center Randomized Controlled Clinical Study on the Effect of L-ornithine on the Efficacy of Ustekinumab in Patients With Crohns Disease
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical trial is to evaluate the effect of supplementing L-ornithine compared to the control group on the efficacy of Ustekinumab in patients with Crohns disease and to summarize the role of supplementing L-ornithine in the treatment of CD patients
Participants will be randomized into two groups the L-ornithine supplementation group and the control group The patients in the L-ornithine supplementation group received oral ornithine capsules for 8 weeks The control group did not receive additional intervention Follow up once a week and after the study patients will come to the hospital to finish the evaluation indicators
Participants will be randomized into two groups the L-ornithine supplementation group and the control group The patients in the L-ornithine supplementation group received oral ornithine capsules for 8 weeks The control group did not receive additional intervention Follow up once a week and after the study patients will come to the hospital to finish the evaluation indicators
Detailed Description:
The goal of this clinical trial is to evaluate the effect of supplementing L-ornithine compared to the control group on the efficacy of Ustekinumab in patients with Crohns disease and to summarize the role of supplementing L-ornithine in the treatment of CD patients
Participants will be randomized into two groups the L-ornithine supplementation group and the control group Patients in the L-ornithine supplementation group take oral ornithine capsules twice a day three capsules per time for 8 weeks each containing 500mg of L-ornithine The control group did not receive additional intervention Follow up once a week and after the study patients will come to the hospital to finish the evaluation indicators
Participants will be randomized into two groups the L-ornithine supplementation group and the control group Patients in the L-ornithine supplementation group take oral ornithine capsules twice a day three capsules per time for 8 weeks each containing 500mg of L-ornithine The control group did not receive additional intervention Follow up once a week and after the study patients will come to the hospital to finish the evaluation indicators
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None